Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2024

Intracranial Outcomes of 1L Selpercatinib in Advanced RET Fusion-positive (RET+) NSCLC: LIBRETTO-431 Study (#259)

Maurice Pérol 1 , Ben J. Solomon 2 , Koichi Goto 3 , Keunchil Park 4 , Ernest Nadal 5 , Emilio Bria 6 , Claudio Martin 7 , Jair Bar 8 , Justin Williams 9 , Tarun Puri 9 , Jian Li 10 , Minji Uh 9 , Boris Lin 9 , Caicun Zhou 11 , Aarohan Pruthi 9
  1. Centre Léon Bérard, Lyon, France
  2. Peter MacCallum Cancer Institute, Melbourne, Australia
  3. National Cancer Center Hospital East, Chiba, Japan
  4. Samsung Medical Center, Seoul, South Korea
  5. Institut Català d’Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
  6. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
  7. Instituto Alexander Fleming, Buenos Aires, Argentina
  8. Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel
  9. Eli Lilly, Indianapolis, IN, USA
  10. Loxo@Lilly , Indianapolis, IN, USA
  11. Shanghai Pulmonary Hospital, Shanghai, China

Selpercatinib, a highly selective, CNS active RET inhibitor is approved for treatment of advanced RET+ NSCLC. LIBRETTO-431 is the first study comparing intracranial (IC) efficacy of a targeted therapy to chemo/immunotherapy (IO) in patients with NSCLC.

LIBRETTO-431 (NCT04194944) is a randomized, phase 3 trial comparing 1L selpercatinib vs chemotherapy (cisplatin/carboplatin+pemetrexed) +/- pembrolizumab.  Primary endpoint of PFS by blinded independent central review (BICR) at the pre-planned interim analysis was met. IC analyses included CNS and non-CNS PD, IC PFS and IC responses by BICR per RECIST 1.1 in eligible patients. Adverse events were evaluated in the CNS safety population.

Of 261 patients, 192 were CNS-evaluable (selpercatinib:120, control:72). Baseline characteristics showed the selpercatinib arm having a slightly lower proportion of patients with BICR-assessed baseline brain mets (21% vs 25%) and prior CNS radiotherapy (RT:6% vs 10%) compared to the control arm. Selpercatinib delayed CNS PD as evidenced by a lower 12-month cumulative incidence rate (CIR) for CNS PD, as well as delaying non-CNS PD compared to control in patients with and without brain mets. In patients with measurable brain mets at baseline (n=29), median time to IC response was similar between selpercatinib and control (1.4 vs 1.6 months ); previously reported IC response rates were higher (82% vs 58%) and more durable (12-month DOR rate 76% vs 63%) with selpercatinib vs control (Zhou et al. NEJM 2023). IC responses to selpercatinib were more common in patients without (93%) than with (50%) prior CNS RT.

Selpercatinib delayed IC progression in advanced RET+ NSCLC with/without baseline brain mets and achieved higher IC response compared to chemotherapy+pembrolizumab. LIBRETTO-431 demonstrated IC efficacy improvement of a targeted therapy vs chemo/IO in a biomarker-selected NSCLC population.  These data further support selpercatinib as the preferred 1L regimen in patients with advanced RET+ NSCLC.

Previously presented at ASCO 2024.